Proinflammatory cytokines have a similar ambiguous role; high-dose interleukin-2 (IL-2) has been used to treat melanoma, whereas TNFα is associated with aggressive breast cancer biology [17], and its inhibitor, etanercept, is currently tested in the phase II clinical trial for metastatic breast cancer [18]. Here, IL2 is linked to breast carcinoma.